With Seagen Integration In Sight, Pfizer Reorganizes Commercial And R&D

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company also provided 2024 financial guidance incorporating Seagen, which underwhelmed investors.

Integration
Pfizer updated investors on its Seagen integration plans • Source: Shutterstock

Pfizer Inc.’s $43bn acquisition of Seagen Inc.  has cleared regulatory obstacles and is on track to close on 14 December, leading the company to update investors on its financial outlook and early integration plans. The company had surprises on both fronts: a 2024 financial forecast that underwhelmed investors and a reorganization that will result in the departure of chief commercial officer and biopharmaceuticals president Angela Hwang.

Key Takeaways

  • Pfizer updated investors on its 2024 financial outlook, including Seagen.

Hwang, who has worked for Pfizer for 27 years and was integral to the launch of Pfizer’s COVID-19 vaccine Comirnaty...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.